The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 293, Issue 6, 2007, Pages

  Goel, Reema ^a   Boylan, Brian ^a   Gruman, Lynn ^b,c   Newman, Peter J ^a,c   North, Paula E ^b,c   Newman, Debra K ^a,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CD31; Inflammation; Liver; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; CD31 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; CELL INFILTRATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; FATTY LIVER; FIBROSIS; HISTOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LIVER CELL DAMAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIGENS, CD31; ATHEROSCLEROSIS; DIET, ATHEROGENIC; HEPATITIS; IMMUNOLOGIC FACTORS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; STEATITIS;

EID: 37149007780     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00157.2007     Document Type: Article

References (73)

1. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 40: S34-S38, 2006.
2. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 22, Suppl 2: 71-73, 2005.
3. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16, 2006.
4. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-β links inflammation to obesity-induced insulin resistance. Nat Med 11: 191-198, 2005.
5. Becker HM, Chen M, Hay JB, Cybulsky MI. Tracking of leukocyte recruitment into tissues of mice by in situ labeling of blood cells with the fluorescent dye CFDA SE. J Immunol Methods 286: 69-78, 2004.
6. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25: 1045-1050, 2005.
7. Burke MD. Liver function: test selection and interpretation of results. Clin Lab Med 22: 377-390, 2002.
8. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11: 183-190, 2005.
9. Carrithers M, Tandon S, Canosa S, Michaud M, Graesser D, Madri JA. Enhanced susceptibility to endotoxic shock and impaired STAT3 signaling in CD31-deficient mice. Am J Pathol 166: 185-196, 2005.
10. Cepinskas G, Savickiene J, Ionescu CV, Kvietys PR. PMN transendothelial migration decreases nuclear NFκB in IL-1β-activated endothelial cells: role of PECAM-1. J Cell Biol 161: 641-651, 2003.
11. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99: 1497-1502, 2004.
12. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 21: 702-707, 2005.
13. Chosay JG, Fisher MA, Farhood A, Ready KA, Dunn CJ, Jaeschke H. Role of PECAM-1 (CD31) in neutrophil transmigration in murine models of liver and peritoneal inflammation. Am J Physiol Gastrointest Liver Physiol 274: G776-G782, 1998.
14. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40: S5-S10, 2006.
15. Cogger VC, Muller M, Fraser R, McLean AJ, Khan J, Le Couteur DG. The effects of oxidative stress on the liver sieve. J Hepatol 41: 370-376, 2004.
16. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44: 197-208, 2006.
17. Day BJ, Shawen S, Liochev SI, Crapo JD. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther 275: 1227-1232, 1995.
18. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16: 663-678, 2002.
19. Day CP. From fat to inflammation. Gastroenterology 130: 207-210, 2006.
20. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
21. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 46: 2050-2068, 2000.
22. Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H, Spellberg J, Luis de la Pompa J, Elia A, Wakeham A, Karan-Tamir B, Muller WA, Senaldi G, Zukowski MM, Mak TW. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 162: 3022-3030, 1999.
23. Duvnjak M, Virovic L. [Non-alcoholic steatohepatitis]. Acta Med Croatica 57: 189-199, 2003.
24. Elrayess MA, Webb KE, Bellingan GJ, Whittall RA, Kabir J, Hawe E, Syvanne M, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Miller GJ, Humphries SE. R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis 177: 127-135, 2004.
25. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107: 535-541, 2006.
26. Fang L, Wei H, Chowdhury SH, Gong N, Song J, Heng CK, Sethi S, Koh TH, Chatterjee S. Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. Indian J Med Res 121: 92-99, 2005.
27. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
28. Gauuan PJ, Trova MP, Gregor-Boros L, Bocckino SB, Crapo JD, Day BJ. Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues. Bioorg Med Chem 10: 3013-3021, 2002.
29. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle NH, Engelhardt B, Madri JA. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 109: 383-392, 2002.
30. Grubb SC, Churchill GA, Bogue MA. A collaborative database of inbred mouse strain characteristics. Bioinformatics 20: 2857-2859, 2004.
31. Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagata Y, Miyazaki K, Kusuhara M, Okazaki M, Matsubara O, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 280: 7002-7009, 2005.
32. Jackson DE. The unfolding tale of PECAM-1. FEBS Lett 540: 7-14, 2003.
33. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol 15: 718-724, 2000.
34. Jaeschke H. Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol Gastrointest Liver Physiol 273: G602-G611, 1997.
35. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sorensen HT. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study. Hepatogastroenterology 50: 2101-2104, 2003.
36. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
37. Koteish A, Mae DA. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16: 679-690, 2002.
38. Listi F, Candore G, Lio D, Cavallone L, Colonna-Romano G, Caruso M, Hoffmann E, Caruso C. Association between platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31) polymorphisms and acute myocardial infarction: a study in patients from Sicily. Eur J Immunogenet 31: 175-178, 2004.
39. Liu Y, Bubolz AH, Shi Y, Newman PJ, Newman DK, Gutterman DD. Peroxynitrite reduces the endothelium-derived hyperpolarizing factor component of coronary flow-mediated dilation in PECAM-1-knockout mice. Am J Physiol Regul Integr Comp Physiol 290: R57-R65, 2006.
40. Loria P, Leonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 17: 684-698, 2007.
41. Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, Newman PJ. Endothelial cell PECAM-1 confers protection against endotoxic shock. Am J Physiol Heart Circ Physiol 288: H159-H164, 2005.
42. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9: 637-642, 2006.
43. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40: S17-S29, 2006.
44. Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 40: S30-S33, 2006.
45. Neubauer K, Wilfling T, Ritzel A, Ramadori G. Platelet-endothelial cell adhesion molecule-1 gene expression in liver sinusoidal endothelial cells during liver injury and repair. J Hepatol 32: 921-932, 2000.
46. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219, 2003.
47. Newman PJ. Switched at birth: a new family for PECAM-1. J Clin Invest 103: 5-9, 1999.
48. Newman PJ, Berndt MC, Gorski J, White GC, Lyman S, Paddock C, Muller WA. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247: 1219-1222, 1990.
49. Newton-Nash DK, Newman PJ. A new role for Platelet-Endothelial Cell Adhesion Molecule-1 (CD31): inhibition of TCR-mediated signal transduction. J Immunol 163: 682-688, 1999.
50. Novinska MS, Pietz BC, Ellis TM, Newman DK, Newman PJ. The alleles of PECAM-1. Gene 376: 95-101, 2006.
51. Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 97: 75-81, 1998.
52. Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 97: 1727-1732, 2001.
53. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 42: 928-940, 2005.
54. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44: 232-263, 2007.
55. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 43: S54-S62, 2006.
56. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 9: 218-232, 2007.
57. Rathore V, Stapleton MA, Hillery CA, Montgomery RR, Nichols TC, Merricks EP, Newman DK, Newman PJ. PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets. Blood 102: 3658-3664, 2003.
58. Sasaoka T, Kimura A, Hohta SA, Fukuda N, Kurosawa T, Izumi T. Polymorphisms in the platelet-endothelial cell adhesion molecule-1 (PECAM-1) gene, Asn563Ser and Gly670Arg, associated with myocardial infarction in the Japanese. Ann NY Acad Sci 947: 259-269, 2001.
59. Schenkel AR, Chew TW, Muller WA. Platelet endothelial cell adhesion molecule deficiency or blockade significantly reduces leukocyte emigration in a majority of mouse strains. J Immunol 173: 6403-6408, 2004.
60. Shibata Y, Juji T, Tohyama H, Sakamoto H, Ozawa N, Kano K. Mixed passive hemagglutination with soluble platelet antigens. Int Arch Allergy Appl Immunol 74: 93-96, 1984.
61. Simmons DL, Walker C, Power C, Pigott R. Molecular cloning of CD31, a putative intercellular adhesion molecule closely related to carcinoembryonic antigen. J Exp Med 171: 2147-2152, 1990.
62. Stockinger H, Gadd SJ, Eher R, Majdic O, Schreiber W, Kasinrerk W, Strass B, Schnabl E, Knapp W. Molecular characterization and functional analysis of the leukocyte surface protein CD31. J Immunol 145: 3889-3897, 1990.
63. Tada Y, Koarada S, Morito F, Ushiyama O, Haruta Y, Kanegae F, Ohta A, Ho A, Mak TW, Nagasawa K. Acceleration of the onset of collagen-induced arthritis by a deficiency of platelet endothelial cell adhesion molecule 1. Arthritis Rheum 48: 3280-3290, 2003.
64. Thompson RD, Noble KE, Larbi KY, Dewar A, Duncan GS, Mak TW, Nourshargh S. Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 97: 1854-1860, 2001.
65. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 278: 42774-42784, 2003.
66. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42: 473-480, 2005.
67. Warren A, Le Couteur DG, Fraser R, Bowen DG, McCaughan GW, Bertolino P. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44: 1182-1190, 2006.
68. Wei H, Fang L, Chowdhury SH, Gong N, Xiong Z, Song J, Mak KH, Wu S, Koay E, Sethi S, Lim YL, Chatterjee S. Platelet-endothelial cell adhesion molecule-1 gene polymorphism and its soluble level are associated with severe coronary artery stenosis in Chinese Singaporean. Clin Biochem 37: 1091-1097, 2004.
69. Wenzel K, Baumann G, Felix SB. The homozygous combination of Leu125Val and Ser563Asn polymorphisms in the PECAM1 (CD31) gene is associated with early severe coronary heart disease. Hum Mutat 14: 545, 1999.
70. Wilkinson R, Lyons AB, Roberts D, Wong MX, Bartley PA, Jackson DE. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease. Blood 100: 184 -193, 2002.
71. Wong MX, Hayball JD, Hogarth PM, Jackson DE. The inhibitory co-receptor, PECAM-1 provides a protective effect in suppression of collagen-induced arthritis. J Clin Immunol 25: 19-28, 2005.
72. Wong MX, Roberts D, Bartley PA, Jackson DE. Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation. J Immunol 168: 6455-6462, 2002.
73. Wullaert A, van LG, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 28: 365-386, 2007.